EXAS

Exact Sciences

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Diagnostics & Research

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

67

Business Summary

Exact Sciences is a molecular diagnostics company focused on providing cancer screening and diagnostic tests. Its primary products include Cologuard for non-invasive colorectal cancer screening and Oncotype DX for genomic cancer testing.

 


Analyze EXAS on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$19,733

Forward P/E

55

PEG

2.3

PRICE TO SALES

6

PRICE TO BOOK

8.2

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$1.10

Next Year EPS Growth Estimate

$1.88

Next Year Revenue Growth Estimate

12.40%

Return on Equity (ROE)

-8.70%

FREE CASH FLOW

Operating Margin

-6.10%

Debt-to-Equity

1.1

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze EXAS on TradingView

Gainseekers Quantitative Analysis

Summary

Exact Sciences is a $19,733 million company in the Healthcare sector currently operating with an EPS of -$1.10 and an operating margin of -6.10%. The company is not profitable, with a Return on Equity of -8.70%, but is expected to see sales growth of 12.40% next year. High institutional ownership of 86.60% indicates significant professional investor interest.

AI Exposure / Tech Reliance

The provided financial data does not contain specific metrics regarding AI exposure or technology reliance.

The Bull Case

The bull case is supported by strong expected sales growth of 12.40% and a projected EPS of $1.88 next year. Additionally, the mean consensus target price is $101.44, suggesting potential upside from current levels.

The Bear Case

The bear case centers on the company's current unprofitability, with a negative Return on Equity of -8.70% and a Debt / Equity ratio of 1.1. The stock trades at high forward multiples, including a Forward P/E of 55 and a Price / Sales of 6.

Market Sentiment & Smart Money

Short Interest %

3.50%

Analyst Consensus

2.91

Average Analyst Price Target

$101.44

Institutional Ownership %

86.60%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.